BioCentury | Nov 15, 2019
Product Development

Minerva on the verge in neuropsychiatry with two compounds close to verdict

Minerva Neurosciences is on the precipice of two clinical readouts that could determine whether its founding bet on a pair of neuropsychiatry compounds from Mitsubishi Tanabe has panned out. Neither molecule represents a shift from...
BioCentury | Jun 21, 2019
Company News

June 20 Company Quick Takes: Priority Review for Alexion, Melinta therapies; plus Alimera, Denovo and more

Priority Review for Alexion's Ultomiris sBLA FDA accepted and granted Priority Review to an sBLA from Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) for Ultomiris ravulizumab-cwvz to block complement-mediated thrombotic microangiopathy in patients with atypical hemolytic uremic syndrome....
BioCentury | May 28, 2019
Distillery Therapeutics

Adrenergic receptor inhibitor combo to treat stroke

...DISEASE CATEGORY: Neurology INDICATION: Stroke Mouse studies suggest inhibiting ADRA1, ADRA2 and ADRB could help treat...
...treat acute ischemic stroke. In two mouse models of ischemic stroke, the combination of the ADRA1...
...Riken, Wako, Japan email: monai.hiromu@ocha.ac.jp CONTACT: Hajime Hirase, same affiliaion as above email: hajime.hirase@riken.jp Chris Lieu Riken Adrenergic receptor alpha 1 (ADRA1) Adrenergic...
BioCentury | Apr 11, 2019
Company News

Ocugen to go public via Histogenics reverse merger

Ocugen will reverse merge with Histogenics to form a public company focused on discovering, developing and commercializing therapies for rare eye diseases. Ocugen Inc. (Malvern, Pa.) stockholders will own about 90% of the resulting company,...
BioCentury | Mar 14, 2019
Company News

Tonix's PTSD therapy loses breakthrough therapy designation

...which Tonix said it observed treatment activity in HONOR. Sandi Wong, Staff Writer Tonix Pharmaceuticals Holding Corp. Adrenergic receptor alpha 1 (ADRA1) Serotonin...
BioCentury | Feb 1, 2019
Clinical News

Eyenovia planning NDA in 1Q20 for microdose ophthalmic solution to induce mydriasis

...Inc. (NASDAQ:EYEN), New York, N.Y. Product: MicroStat Business: Ophthalmology Molecular target: Adrenergic receptor α 1 (ADRA1...
BioCentury | Aug 3, 2018
Clinical News

Tonix stops Phase III of PTSD candidate on lack of separation from placebo

...Product: Tonmya (Sublingual TNX-102) Business: Neurology Molecular target: Serotonin (5-HT2A) receptor; Adrenergic receptor α 1 (ADRA1...
...Phase III data Milestone: NA Elizabeth S. Eaton Tonmya (Sublingual TNX-102, TNX-102 SL, cyclobenzaprine) Tonix Pharmaceuticals Holding Corp. Adrenergic receptor alpha 1 (ADRA1) Serotonin...
BioCentury | May 18, 2018
Clinical News

FDA approves US WorldMeds' Lucemyra for opioid withdrawal

FDA approved Lucemyra lofexidine from US WorldMeds LLC (Louisville, Ky.) for the mitigation of withdrawal symptoms to facilitate abrupt discontinuation of opioids in adults. According to the agency, Lucemyra is the first non-opioid drug approved...
BioCentury | May 16, 2018
Company News

FDA approves US WorldMeds' Lucemyra for opioid withdrawal

FDA approved Lucemyra lofexidine from US WorldMeds LLC (Louisville, Ky.) for the mitigation of withdrawal symptoms to facilitate abrupt discontinuation of opioids in adults. According to the agency, Lucemyra is the first non-opioid drug approved...
BioCentury | Apr 13, 2018
Clinical News

Ocugen reports Phase II data for dry eye disease candidate

Ocugen Inc. (Malvern, Pa.) reported data from a Phase II trial showing that dry eye disease candidate OCU310 met the primary endpoint of tolerability over a 12-week period. The company said the trial was not...
Items per page:
1 - 10 of 319